ArticleFrontiers in cellular and infection microbiology2026
External quality assurance of molecular serotype detection of dengue virus RNA among virus research and diagnostic laboratories in India.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: External Quality Assessment Schemes (EQAS) are essential for ensuring the accuracy, reliability, and comparability of molecular diagnostic testing across laboratory networks. To strengthen dengue molecular surveillance and laboratory quality systems in India, a Pan-Dengue Molecular Serotyping EQAS was developed and implemented among Virus Research and Diagnostic Laboratories (VRDLs) in India. Methods: A nationwide EQAS was conducted in three rounds between December 2024 and February 2026. Proficiency testing panels consisting of five coded lyophilized serum samples (500 µL each) containing dengue-positive and dengue-negative specimens were prepared, characterized, validated, and distributed to participating laboratories. Homogeneity and stability assessments were performed prior to distribution. Participating laboratories tested the panels using their routine molecular diagnostic workflows and reported dengue detection and serotype identification results through the National Institute of Epidemiology (NIE) PT Panel Portal. Laboratory performance was evaluated based on concordance with assigned reference results. Results: A total of 34, 40, and 56 laboratories enrolled in Round 1, Round 1 Phase-II, and Round 2, respectively. The corresponding response rates were 91.2%, 95.0%, and 94.6%. Complete concordance was achieved by all reporting laboratories in Round 1 (31/31) and Round 1 Phase-II (38/38). In Round 2, 50/53 laboratories (94.3%) achieved 100% concordance, while two and one laboratory achieved 80% and 60% concordance, respectively. The overall pass rate across all rounds was 97.5%. Conclusion: The Pan-Dengue Molecular Serotyping EQAS highlighted a high level of proficiency among participating laboratories and effectively strengthened molecular diagnostic quality assurance within the national laboratory network. Regular implementation of such programmes will support reliable dengue surveillance, continuous quality improvement, and enhanced preparedness for dengue outbreaks in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.